MAZE Maze Therapeutics, Inc.
Healthcare$26.04+0.00%OpenMarket Cap: $1.44B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.07
P/S
71.34
EV/EBITDA
-10.21
DCF Value
$3.83
FCF Yield
-8.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.0%
Operating Margin
-670.3%
Net Margin
-612.7%
ROE
-36.6%
ROA
-29.2%
ROIC
-33.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.0M | 97.8% | $-26.6M | $-24.2M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-38.1M | $-34.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-142.9M | $-131.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-33.0M | $-30.1M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-36.5M | $-33.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-35.4M | $-32.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-29.7M | $-29.6M | $— | — |
| FY null | $167.5M | 100.0% | $57.6M | $52.2M | $— | — |
| Q3 null | $2.5M | 100.0% | $-24.2M | $-24.8M | $— | — |
| Q2 null | $165.0M | 100.0% | $139.6M | $139.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-28.0M | $-32.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-23.1M | $-26.6M | $-0.61 | — |